Since the official launching of the TIF Industry Circle in 2012, the Thalassaemia International Federation (TIF) receives funding from pharmaceutical industries in the pursuit of their common interest in haemoglobin disorders (thalassaemia and sickle cell disease) and in the development of technologies relating to their prevention, treatment and monitoring.
The overall proportion of industry related funding (sub-total in %) is 17.09% and the non-industry funding is 82.85%. The highest contribution from a single company is 8.47 %.
TIF receives funding through Donations, Project funding, Industry, Memberships, subscriptions and others.
Project funding includes International Conferences, Memberships and subscriptions and other.